Cynda(SH:603086) EBSCN·2024-05-21 10:02Investment Rating - The report maintains a "Buy" rating for the company [14] Core Views - The company has successfully passed the registration review for its new herbicide, Pyrazol Quinclorac, which is a novel HPPD inhibitor with high efficiency, low toxicity, and low residue [14][17] - The company is enhancing its production capacity and product layout, with significant investments in new product lines and automated formulation projects to support rapid business expansion [6][16] - The company is making steady progress in international market registrations and commercial collaborations for its key products, with successful registrations in major markets such as Australia, the EU, and the US [7][16] Financial Performance - In 2023, the company reported a revenue of 2.482 billion yuan, a decrease of 20.58% year-on-year, and a net profit attributable to shareholders of -98 million yuan, down 125.68% year-on-year [17][19] - The company’s main products saw a decline in prices, leading to a drop in gross margins, with the gross margin for 2023 at 11.54%, down 15.66 percentage points year-on-year [17][19] - The company forecasts net profits of 0.27 million yuan in 2024, down 84.7%, and expects a gradual recovery in subsequent years with projected profits of 1.46 million yuan in 2025 and 2.56 million yuan in 2026 [17][19] Product Development - The company has developed several patented compounds, including Quinclorac and Benzoyl Pyrazol, which are expected to enter the commercialization phase soon [16] - The company is also focusing on developing unique products such as Fluoropyrazole and 2,4-Dibutyrate, with ongoing registration efforts in various markets [16]